Tharimmune, Inc.

Equities

THAR

US4327052001

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
0.361 ^USD	-1.98%		-4.01%	-29.08%

05-09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	CI

Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 23, 2024 at 08:31 am

Tharimmune, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 9.32 million compared to USD 8.47 million a year ago. Basic loss per share from continuing operations was USD 7.14 compared to USD 18.72 a year ago.

Latest news about Tharimmune, Inc.

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	04-23	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	02-20	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	02-05	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	01-29	CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	12-11	MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	12-11	CI
Sector Update: Health Care Stocks Retreat in Late Afternoon	11-28	MT
Top Midday Decliners	11-28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	11-28	MT
Top Premarket Decliners	11-28	MT
Tharimmune Prices $10 Million Public Share Offering	11-28	MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	11-27	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	11-17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	11-17	MT
Tharimmune to Implement 1-for-25 Reverse Stock Split	11-17	MT
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	11-06	CI
Certain Warrants of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Certain Options of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Tharimmune, Inc.(NasdaqCM:THAR) added to NASDAQ Composite Index	23-09-25	CI
Tharimmune, Inc. has Changed its Ticker to THAR from HILS	23-09-25	CI
Hillstream BioPharma Inc. has Changed its Name to Tharimmune, Inc	23-09-25	CI

Chart Tharimmune, Inc.

Duration

Period

More charts

Company Profile

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.361 USD

Average target price

5 USD

Spread / Average Target

+1,285.04%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-29.08%	4.34M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs